Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis.
Exposure of U937 human leukemic cells to the phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) induces their differentiation into monocyte/macrophage-like cells. This terminal differentiation is associated with a resistant phenotype to apoptosis induced by the topoisomerase II inhibitor etoposide. The inhibition occurs upstream of the mitochondrial release of cytochrome c and the activation of procaspase-2, -3, -6, -7, -8, and -9. By using cell-free systems, it was demonstrated that the mitochondrial pathway to cell death that involves mitochondrial membrane depolarization, cytochrome c release and cytosolic activation of procaspases by cytochrome c/dATP remains functional in TPA-differentiated U937 cells. Accordingly, 2 drugs recently shown to target the mitochondria, namely lonidamine and arsenic trioxide, bypass the resistance of TPA-differentiated U937 cells to classical anticancer drugs. Cell death induced by the 2 compounds is associated with mitochondrial membrane depolarization, release of cytochrome c and Smac/Diablo from the mitochondria, activation of caspases, poly(ADP-ribose) polymerase cleavage and internucleosomal DNA fragmentation. Moreover, the decreased glutathione content associated with the differentiation process amplifies the ability of arsenic trioxide to activate the mitochondrial pathway to cell death. Similar results were obtained by comparing undifferentiated and TPA-differentiated human HL60 leukemic cells. These data demonstrate that mitochondria-targeting agents bypass the resistance to classical anticancer drugs induced by TPA-mediated leukemic cell differentiation. (Blood. 2001;97:3931-3940)
Sordet
O
O
Faculty of Medicine and Pharmacy, INSERM U517 and INSERM U498, IFR 100, 7 boulevard Jeanne d'Arc, 21033 Dijon, France.
Rébé
C
C
Leroy
I
I
Bruey
J M
JM
Garrido
C
C
Miguet
C
C
Lizard
G
G
Plenchette
S
S
Corcos
L
L
Solary
E
E
D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000494:pharmacology*; D020169:Caspases / Q000187:drug effects / Q000502:physiology; D002454:Cell Differentiation / Q000187:drug effects; D002474:Cell-Free System / Q000187:drug effects / Q000201:enzymology; D004351:Drug Resistance; D005047:Etoposide / Q000494:pharmacology; D006801:Humans; D007191:Indazoles / Q000494:pharmacology*; D007938:Leukemia / Q000473:pathology*; D008928:Mitochondria / Q000187:drug effects* / Q000201:enzymology; D010087:Oxides / Q000494:pharmacology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000187:drug effects / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology*; D020298:U937 Cells / Q000187:drug effects / Q000201:enzymology / Q000648:ultrastructure
D000970:Antineoplastic Agents; D001152:Arsenicals; D007191:Indazoles; D010087:Oxides; D019253:Proto-Oncogene Proteins c-bcl-2; D005047:Etoposide; D020169:Caspases; D013755:Tetradecanoylphorbol Acetate; D000077237:Arsenic Trioxide; C016371:lonidamine